Uterine Cancer

Uterine sarcoma is a rare cancer that starts in the muscle (myometrium) or supporting tissues of the uterus (womb) — not in the inner lining (endometrium). It behaves like other soft-tissue sarcomas and is approached differently than endometrial carcinoma.

What makes uterine sarcoma different from other uterine cancers?

Origin: Sarcoma arises from muscle or stromal/connective tissue in the uterus, whereas endometrial carcinoma begins in the endometrial lining. Management, staging, and drug responsiveness differ.
Carcinosarcoma: Although it has features of both carcinoma and sarcoma, it is now classified and staged as an endometrial carcinoma, not a true sarcoma.

Main subtypes

Uterine leiomyosarcoma (LMS)

Develops from the uterine muscle; can grow and spread rapidly.

Endometrial stromal sarcoma (ESS)

Arises from the stromal/supporting tissue of the endometrium; low-grade ESS tends to grow slowly and is often hormone-receptor positive, while high-grade/undifferentiated forms are more aggressive.

Adenosarcoma

Mixed epithelial–stromal tumor that behaves as a sarcoma; treatment and prognosis differ from endometrial carcinoma.

(Uterine sarcoma is uncommon overall; patterns of spread and treatment choices mirror those for other soft-tissue sarcomas, adapted to the pelvic anatomy.)

Signs & Symptoms

Abnormal vaginal bleeding (including postmenopausal bleeding) is the most common symptom
pelvic/abdominal pain or fullness
urinary frequency
vaginal mass.
These symptoms are not specific and warrant evaluation.

Risk factors

Prior pelvic radiation is a recognized risk.
Tamoxifen exposure (for breast cancer) increases risk; people taking tamoxifen should have regular pelvic exams and report any abnormal bleeding promptly.

Diagnosis

Evaluation may include:

help identify a suspicious uterine mass.

(sometimes with hysteroscopy or D&C) is used to confirm histology; the final diagnosis and grade are established by pathology.

is used for staging and surgical planning as with other soft tissue sarcomas

Staging

Uterine sarcoma is staged using FIGO/AJCC TNM systems specific to LMS and ESS. Staging incorporates:

Tumor extent (T)

size and whether the tumor extends beyond the uterus

Nodal status (N)

spread to pelvic/para-aortic nodes

Metastasis (M)

spread to distant organs (e.g., lungs, liver, bone)

Treatment options (by subtype and stage)

Surgery (foundation of care)

For most early‑stage uterine sarcomas, the mainstay is hysterectomy (removal of the uterus) often with bilateral salpingo‑oophorectomy (tubes/ovaries). Lymph nodes are evaluated selectively (e.g., if enlarged on imaging or exam).

Radiation therapy

May be used after surgery in selected cases to lower pelvic recurrence risk (local control), particularly for LMS, though it has not consistently improved overall survival.

Chemotherapy

Considered for higher‑stage disease or when recurrence risk is high; its adjuvant benefit in stage I LMS remains uncertain. For stage II LMS, some experts consider adjuvant chemotherapy; regimens vary and ongoing studies continue to refine indications.

Hormone therapy (especially for ESS):

Low‑grade ESS is frequently ER/PR‑positive and may respond to progestins or other endocrine approaches as part of adjuvant or recurrent‑disease management.

Targeted therapy & immunotherapy:

For advanced or recurrent disease, targeted agents and immunotherapies may be options; enrollment in clinical trials is strongly encouraged given rarity and evolving evidence.

Because uterine sarcoma is rare, many experts recommend clinical-trial participation whenever available to access emerging therapies and contribute to better evidence.

Prognosis

Outcomes vary by histology, stage, grade, and resectability. In general, low-grade ESS has a more favorable outlook than LMS or undifferentiated sarcomas; survival statistics are commonly presented by SEER stage groups (localized/regional/distant). Your physician will interpret what published survival figures mean for your situation.

Follow-Up & Survivorship

Regular follow-up is important to detect and manage recurrence promptly (clinical exam, symptom review, and imaging tailored to subtype and prior stage).
Many people benefit from rehabilitation, sexual health and pelvic floor support, fertility counseling (as appropriate), and psychosocial resources typical for soft-tissue sarcomas.

Why Choose Illinois CancerCare

Multidisciplinary sarcoma expertise—coordinating gynecologic oncology, surgical oncology, medical oncology, radiation oncology, pathology, radiology, and genetics—to tailor staging, surgery, and systemic therapy to your subtype and goals.
Access to clinical trials and evidence aligned options (surgery, radiation, chemotherapy, hormone therapy for ESS, and novel systemic therapies for advanced disease).

Sources & Patient Friendly References

All information was taken from the NCI (National Cancer Institute) and ACS (American Cancer Society).